Traders should watch for a prospectus supplement announcing a priced offering, which typically follows effectiveness within days to weeks for clinical-stage biotechs. Monitor insider buying/selling patterns for signals on whether management views the current valuation as attractive ahead of potential dilution.
How the stock moved after the report
BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 26 $4.80entry
- T+1 · 6mo ago −0.83%α −0.85% · $4.76
- T+5 · 6mo ago −9.58%α −10.80% · $4.34
- T+20 · 5mo ago −15.52%α −13.57% · $4.06
- T+60 · 3mo ago −17.50%α −20.22% · $3.96
Price Chart
How similar events traded
Executive Summary
Protara Therapeutics' registration statement on Form S-3 (File No. 333-295862) was declared effective on May 22, 2026. This enables the company to conduct primary and/or secondary offerings of securities at any time, creating potential dilution overhang for common stock shareholders.
Key Facts
- Form S-3 shelf registration became effective May 22, 2026.
- Registration covers issuance of common stock, preferred stock, warrants, debt securities, and/or units.
- No specific pricing, amount, or intended use of proceeds was disclosed in the effectiveness notice.
- Company is a clinical-stage biotech with $277M market cap and 93% analyst buy rating.
Financial Impact
Undisclosed, no offering size or terms were provided in the effectiveness notice. Shelf registration is effective immediately, so the company can conduct offerings at any time.
Risk Factors
- Immediate risk: company may announce a dilutive offering at any time now that the shelf is effective.
- Clinical-stage biotech with no approved products, pipeline failure could compound dilution risk.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| EFFECT Filing (Primary) | 9999999995-26-001748 |
| Document: 9999999995-26-001748-index.html | 9999999995-26-001748 |
| Document: 9999999995-26-001748.txt | 9999999995-26-001748 |
Track record
13 reports on TARA
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $2.52 Now $2.38 +5.56% settles Feb 12
- Nov 6, 202610d ago 8-K Neutral 4/10 No price data
- Nov 6, 202610d ago Press Release Neutral 4/10 Entry $2.30 Now $2.38 +3.48% settles Feb 4
- Oct 15, 20264w ago Press Release Neutral 3/10 Entry $2.40 Now $2.38 −0.83% settles Jan 12
- Aug 11, 202613w ago 8-K Neutral 4/10 No price data
- Aug 11, 202613w ago Press Release Neutral 4/10 Entry $3.91 to $2.35 Now $2.38 −39.13% ▼ −39.90% −39.41% vs SPY
- Jun 29, 202620w ago 8-K Neutral 2/10 Entry $3.82 to $3.54 Now $2.38 −37.70% ▼ −7.33% −10.15% vs SPY
- May 26, 202625w ago EFFECT Bearish 5/10 Viewing Entry $4.80 to $3.96 Now $2.38 +50.42% ▲ +17.50% +20.22% vs SPY
- May 15, 202626w ago Press Release Bullish 7/10 Entry $5.10 to $3.91 Now $2.38 −53.33% ▼ −23.33% −27.85% vs SPY
- May 13, 202626w ago 8-K Neutral 4/10 No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers